NCT07376382 2026-02-02
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
Clinical Trials
11 trialsNCT05089916 2026-01-14
ROSE
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT06362980 2024-07-10
EGFR
National Cancer Center, China
Phase 1 Recruiting
NCT03810066 2024-05-09
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
University Hospital, Essen
Phase 2 Completed
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT05382728 2024-01-30
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
TYK Medicines, Inc
Phase 3 Recruiting
NCT05693090 2023-03-06
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Phase 1 Withdrawn
NCT04811001 2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT03394118 2021-04-27
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Asan Medical Center
Phase 2 Completed
NCT04575415 2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown